SCHEMBL726323

SCHEMBL726323

CC(C)(C)c1cc(-c2ccc[nH]c2=O)c(O)c(C2CC2c2ccc(NS(C)(=O)=O)cc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.64
KDM1A O60341 5/20 0.38
JAK2 O60674 1/20 0.34
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
NR2F2 P24468 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PDPK1 O15530 1/20 0.32
NR3C2 P08235 1/20 0.32
TRPV1 Q8NER1 1/20 0.32
BRD4 O60885 3/20 0.32
EP300 Q09472 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
EPHX2 P34913 1/20 0.31
NR1H4 Q96RI1 1/20 0.31
AURKA O14965 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3423335 0.88 CYP3A4 (0.57) CYP3A4KDM1AJAK2PDPK1NR3C2
SCHEMBL725100 0.85 CYP3A4 (0.46) CYP3A4KDM1AJAK2TRPV1BRD4
SCHEMBL2111644 0.84 CYP3A4 (0.69) CYP3A4KDM1AJAK2NPC1LMNA
SCHEMBL3425300 0.80 CYP3A4 (0.49) CYP3A4KDM1AJAK2TRPV1
SCHEMBL2111363 0.78 CYP3A4 (1.00) CYP3A4KDM1AJAK2NR3C2
SCHEMBL725581 0.78 CYP3A4 (1.00) CYP3A4KDM1AJAK2NR3C2
SCHEMBL2691329 0.78 CYP3A4 (0.51) CYP3A4KDM1AJAK2NPC1LMNA
SCHEMBL2112475 0.78 CYP3A4 (1.00) CYP3A4KDM1AJAK2NR3C2
SCHEMBL1542584 0.77 CYP3A4 (0.62) CYP3A4PDPK1NR3C2TRPV1BRD4
SCHEMBL1542324 0.77 CYP3A4 (0.62) CYP3A4TRPV1EP300EPHX2NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158803-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-04-17 US claimed
EP-2421831-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP claimed
WO-2010122082-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO claimed
US-20100272677-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS LEE EUN KYUNG 2010-10-28 US claimed
US-8158803-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-04-17 US disclosed
US-20100272677-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS LEE EUN KYUNG 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100272677-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, RRM2B CYP3A4 417/4885KDM1A 1567/4885JAK2 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.